FDA Calendar

Biotech Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

The catalyst date is the LATEST expected date for the catalyst to occur by.  For example, if the catalyst date is 12/31/17, the event is expected to occur BY 12/31/17. It does NOT necessarily mean that the catalyst will occur ON this date. In most cases it will occur BEFORE.

Please refer to the “FDA Calendar Glossary” for a list of terms used in the FDA Decision Calendar.

AMEX and NASDAQ companies are listed. Generally no OTC/PINK companies are listed unless the upcoming catalyst is a PDUFA event. LARGE cap companies are generally NOT featured.

Pipeline data are current and updated daily! Click on the date for the source of the catalyst.

Financial data updated each evening.

Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watchlist and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates

Showing 393 drugs
Ticker Price Drug Stage Catalyst
EGLT
$8.77
+0.47  (+5.66%)
Egalet-001
Abuse-Deterrent Morphine
PDUFA
PDUFA October 14 2016 delayed due to label issues. Advisory Committee Meeting August 4 2016 voted 18 to 1 to recommend approval. Company presentation November 14 mentions that a decision is due 4Q 2016.
SCYX
$3.53
+0.01  (+0.28%)
Intravenous SCY-078
Phase 1
Safety and pharmacokinetics data due November 2016.
ATOS
$1.79
-0.01  (-0.57%)
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer
Phase 2
EXACT DATE UNSURE - Phase 2 initiated March 2016 - presentation due San Antonio Breast Cancer Symposium to be held December 6-10, 2016.
CORT
$8.28
+0.36  (+4.61%)
Mifepristone in combination with eribulin
Cancer - triple-negative breast cancer
Phase 1/2
EXACT DATE UNSURE - Phase 1/2 final data due at The San Antonio Breast Cancer Symposium Dec 6-10, 2016.
CASC
$5.68
-0.23  (-3.89%)
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 1b
Phase 1b updated data to be presented at SABCS December 9, 2016; 7:30 a.m.—9:00 a.m. CST.
EIGR
$11.90
-0.75  (-5.93%)
Subcutaneous exendin
Post-Bariatric Hypoglycemia (PBH)
Phase 2
Phase 2 interim data to be presented December 9, 2016.
IMMU
$3.69
+0.06  (+1.65%)
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2
Phase 2 updated data due December 9, 2016 at SABCS. Phase 3 to be initiated late 2016 or early 2017. BLA filing due mid-2017.
ALNY
$42.25
+1.44  (+3.54%)
ALN-TTRsc02
ATTR amyloidosis
Phase 1
Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due December 16, 2016.
CEMP
$7.70
+0.35  (+4.76%)
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
PDUFA
PDUFA December 27 2016. Antimicrobial Drugs Advisory Committee voted on 7-6 in favor that benefit exceeds risks.
AAAP
$30.14
+0.1  (+0.33%)
Lutathera
Inoperable progressive midgut NETs
PDUFA
PDUFA date under priority review December 28, 2016. Signalled November 28, 2016 that delay is likely.
CEMP
$7.70
+0.35  (+4.76%)
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
PDUFA
PDUFA December 28 2016. Antimicrobial Drugs Advisory Committee voted on 7-6 in favor that benefit exceeds risks.
ABUS
$3.25
+0.1  (+3.17%)
ARB-1467
Hepatitis B (HBV)
Phase 2
Phase 2 single dose data released September 2016, multiple dose data due 4Q 2016.
ACAD
$26.76
-0.48  (-1.76%)
Pimavanserin
Alzheimer’s disease psychosis
Phase 2
Phase 2 top-line data due 4Q 2016.
ACOR
$21.40
+0.2  (+0.94%)
Dalfampridine
Post stroke deficits
Phase 3
Phase 3 data due 4Q 2016.
ACRX
$3.25
+0.1  (+3.17%)
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
NDA Filing
Phase 3 data released September 15, 2016. NDA filing due 4Q 2016.
ADHD
$1.99
-0.1  (-4.78%)
MDX (Metadoxine Extended Release (MG01CI))
Adult ADHD
Phase 3
Clinical hold placed September 29, 2016. Intends to meet with the FDA in December 2016 to discuss proposals + seek guidance on the possibility of conducting certain analyses of the efficacy data already collected in the MEASURE study.
AGIO
$49.56
+1.7  (+3.55%)
AG-221
Advanced hematologic malignancies with an IDH2 mutation
NDA Filing
NDA filing due by the end of 2016
AKAO
$5.25
+0.22  (+4.37%)
Plazomicin - EPIC trial
Complicated urinary tract infections (cUTI)
Phase 3
Phase 3 top-line results due by end of 2016.
AKAO
$5.25
+0.22  (+4.37%)
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)
Phase 3
Phase 3 topline data due by end of 2016.
ANTH
$1.91
-0.09  (-4.5%)
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3
Phase 3 initiated October 2015. Top-line data due 4Q 2016.
ATRS
$2.03
+0.03  (+1.5%)
VIBEX QuickShot
Testosterone deficiency
NDA Filing
NDA to be filed 4Q 2016.
AVIR
$1.32
+0.06  (+4.76%)
BTA585
Respiratory syncytial virus (RSV)
Phase 2a
Phase 2a enrollment completed November 2016. Top-line data due around the end of 2016.
BDSI
$1.85
+0.25  (+15.62%)
Clonidine gel
Painful diabetic neuropathy (PDN)
Phase 2b
Phase 3 trial failed to meet primary endpoint late March 2015. New trial initiated late 2015. Data due from Phase 2b trial in December 2016.
CHRS
$28.15
+0.3  (+1.08%)
CHS-1420
Psoriasis
Phase 3
Phase 3 top-line data met endpoints August 2016. Full data due 4Q 2016 with BLA filing to follow.
CTRV
$1.98
-0.03  (-1.49%)
CMX157
Hepatitis B
Phase 2
Phase 2 interim data presented October 2016. Data from remaining two cohorts due by end of 2016.
EIGR
$11.90
-0.75  (-5.93%)
Subcutaneous exendin
Hypoglycemia post-gastric bypass surgery
Phase 2
Phase 2 data due by the end of 2016.
EYEG
$1.72
+0.11  (+6.83%)
EGP-437
Ocular inflammation and pain post cataract surgery
Phase 1/2
Phase 1/2 top-line data released July 2016. Further data due 4Q 2016.
FLXN
$19.55
+0.06  (+0.31%)
Zilretta - FX006
Osteoarthritis of the knee
NDA Filing
NDA to be filed December 2016.
GLPG
$58.95
+0.71  (+1.22%)
GLPG1837
Cystic Fibrosis
Phase 2
Phase 2 data due 4Q 2016.
IRWD
$15.24
+0.35  (+2.35%)
Linaclotide Colonic Release
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2b
Phase 2b data due 4Q 2016.
LIFE
$3.55
+0.15  (+4.41%)
Resolaris
Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2
Data from first four patients due December 2016.
LIFE
$3.55
+0.15  (+4.41%)
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B
Phase 1/2
Phase 1b/2 data due December 2016.
LXRX
$15.49
-0.26  (-1.65%)
Sotagliflozin
Type 1 Diabetes
Phase 3
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial due in December 2016.
MDGN
$5.35
+0.09  (+1.71%)
NFC-1 - SAGA
mGluR mutation positive ADHD
Phase 2/3
Phase 2/3 initiated June 2016. Initial top-line data are due around the end of 2016.
NEOS
$7.05
+0.2  (+2.92%)
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)
NDA Filing
CRL issued November 2015. NDA to be resubmitted 4Q 2016.
NKTR
$12.95
+0.62  (+5.03%)
Cipro DPI
Bronchiectasis
Phase 3
Phase 3 trial completion due 4Q 2016.
NKTR
$12.95
+0.62  (+5.03%)
Fovista
Wet-AMD
Phase 3
Phase 3 initial top-line data due 4Q 2016 from first two trials. Data from third trial due 2H 2017.
NVCR
$8.75
+0.4  (+4.79%)
Tumor Treating Fields (TTFields) - INNOVATE
Ovarian cancer
Phase 2
Phase 2 data due December 2016.
NVCR
$8.75
+0.4  (+4.79%)
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer
Phase 2
Phase 2 data due December 2016.
OCUL
$9.28
-0.09  (-0.96%)
DEXTENZA
Ocular inflammation and pain following cataract surgery
NDA Filing
CRL July 25 2016 - due to manufacturing deficiencies. NDA to be resubmitted by the end of 2016.
OPHT
$35.79
+1.19  (+3.44%)
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 3
Phase 3 initial top-line data due 4Q 2016 from first two trials. Data from third trial due 2H 2017.
OPK
$10.81
-0.12  (-1.11%)
hGH-CTP
Adults - growth hormone deficiency
Phase 3
Initiated Phase 3 Jun 2013. Phase 3 data due 4Q 2016.
OTIC
$17.40
+1.2  (+7.41%)
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2
Second Phase 2 trial initiated March 2016. Due to be completed 4Q 2016
PGNX
$8.87
+0.31  (+3.62%)
1404
Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)
Phase 3
Phase 3 interim analysis due 4Q 2016.
PLX
$0.30
-0.01  (-0.97%)
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2
Phase 2 initiated July 2016. Data are due around the end of 2016.
PRTO
$9.90
+0  (+0%)
Vonapanitase (PRT-201) PATENCY-1
Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)
Phase 3
Phase 3 initiated July 2014. Data due December 2016.
RDHL
$11.29
+0.01  (+0.09%)
RHB-104 MAP US
Crohn’s disease
Phase 3
Phase 3 DSMB safety analysis due 4Q 2016. Interim efficacy analysis due 2Q 2017.
RDHL
$11.29
+0.01  (+0.09%)
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2a
Phase 2a data due 4Q 2016.
RIGL
$2.63
-0.02  (-0.75%)
Fostamatinib
IgA nephropathy
Phase 2
Phase 2 data due by the end of 2016
RVNC
$17.20
+0.4  (+2.38%)
RT002
Cervical dystonia
Phase 2
Phase 2 initiated September 2015. Further data to be released 4Q 2016.
RXII
$1.70
-0.05  (-2.86%)
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2
Phase 2 enrollment completed 3Q 2016. Preliminary data readout due 4Q 2016. Final readout 2H 2017.
RXII
$1.70
-0.05  (-2.86%)
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2
Phase 2 enrollment to be completed 1Q 2017. Data readouts due 4Q 2016 and 2Q 2017.
SGYP
$5.54
+0.06  (+1.09%)
Plecanatide
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3
Phase 3 data from first trial met primary endpoint - December 9, 2016. Data from second trial are also due in December 2016.
TCON
$5.40
-0.25  (-4.42%)
TRC105
Soft tissue sarcomas
Phase 2
Phase 2 data due late 2016.
VTVT
$5.35
+0.21  (+4.09%)
TTP273 - LOGRA
Type 2 Diabetes
Phase 2
Phase 2 initiated January 2016. Topline results are expected at the end of 2016.
VCEL
$2.40
+0.05  (+2.13%)
MACI
Focal chondral cartilage defects in the knee.
PDUFA
PDUFA date January 3 2017
OTIC
$17.40
+1.2  (+7.41%)
OTIPRIO
Acute otitis externa
Phase 3
Phase 3 initiated June 2016. Announced November 30, 2016 that data are due within 4-6 weeks - i.e. December 28~January 11, 2017.
TSRO
$131.54
-3.31  (-2.46%)
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
PDUFA
PDUFA January 11 2017
AGRX
$6.71
-0.05  (-0.74%)
Twirla
Contraceptive patch
Phase 3
CRL issued 2013. Phase 3 top-line data due early January 2017.
CORI
$5.02
+0.23  (+4.8%)
Twirla
Contraceptive patch
Phase 3
CRL issued 2013. Phase 3 top-line data due early January 2017.
ITEK
$6.80
-0.15  (-2.16%)
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 3
Phase 3 initiated October 2015. Top-line data due early January 2017. January 13 listed as last possible date assuming company guidance of an “early January” data release.
INCY
$100.61
-2.27  (-2.21%)
Baricitinib
Rheumatoid arthritis
PDUFA
Announced January 19 2016 that their NDA Filing has been submitted by partner Eli Lilly
SGYP
$5.54
+0.06  (+1.09%)
Plecanatide
Chronic idiopathic constipation (CIC)
PDUFA
PDUFA January 29 2017
AERI
$36.93
-1.63  (-4.22%)
Rhopressa
Glaucoma
NDA Filing
NDA Filing September 6, 2016 withdrawn due to third party manufacturing issues. NDA to be refiled in January 2017.
AST
$4.30
+0  (+0%)
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2
Phase 1/2 six-month data due January 2017. Interim data presented September 14, 2016.
BTX
$3.32
-0.08  (-2.06%)
AST-OPC1
Cervical spinal cord injury
Phase 1/2
Phase 1/2 topline data due January 2017.
DMTX
$4.70
+0.05  (+1.08%)
DTX101
hemophilia B
Phase 1/2
Phase 1/2 initial data due January 2017.
FGEN
$22.35
-0.2  (-0.89%)
FG-3019
Pancreatic cancer
Phase 2
Phase 2 ongoing. Data due January 2017.
GNCA
$4.36
+0.09  (+2.11%)
GEN-003
Genital herpes
Phase 2b
Phase 2b virologic efficacy data released September 2016. 6-month efficacy data due January 2016. Phase 3 to commence 2H 2017.
NBIX
$41.71
-1.23  (-2.86%)
NBI-98854 (Valbenazine)
Tourette syndrome
Phase 2
Phase 2 data due January 2017.
TENX
$1.98
+0.03  (+1.54%)
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery
Phase 3
Phase 3 top line data due January 2017.
AVIR
$1.32
+0.06  (+4.76%)
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2b
Phase 2b top-line data due early February 2017.
CATB
$3.61
+0.09  (+2.56%)
CAT-1004
Duchenne muscular dystrophy (DMD)
Phase 2
Phase 2 data first half of 1Q 2017.
CLVS
$36.46
-0.88  (-2.36%)
Rucaparib ARIEL2
Cancer - ovarian second line
PDUFA priority review
PDUFA under priority review February 23, 2017. No Advisory Committee meeting required
AXON
$14.25
-0.08  (-0.57%)
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 2
Phase 2 data due February 2017.
LXRX
$15.49
-0.26  (-1.65%)
Telotristat etiprate
Carcinoid Syndrome
PDUFA priority review
PDUFA date under priority review extended by three months to February 28, 2017.
RDUS
$47.07
-6.43  (-12.02%)
Abaloparatide-SC
Osteoporosis
PDUFA
PDUFA March 30 2017
ABEO
$5.15
-0.65  (-11.21%)
ABO-102
Sanfilippo syndrome type A (MPS IIIA)
Phase 1/2
Phase 1/2 enrollment completed August 2016. Update provided October 2016 with more analysis due 1Q 2017.
ACOR
$21.40
+0.2  (+0.94%)
CVT-301
OFF episodes of Parkinson’s disease (PD)
Phase 3
Phase 3 data due 1Q 2017.
ACRS
$29.28
+0.31  (+1.07%)
A-101
Seborrheic keratosis (SK)
NDA Filing
Phase 3 trial met endpoints - November 15, 2016. NDA filing 1Q 2017.
AEZS
$3.80
+0.1  (+2.7%)
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3
Phase 3 data due early 2017 with NDA filing due 1H 2017 pending positive data.
AEZS
$3.80
+0.1  (+2.7%)
Zoptrex
Endometrial cancer
Phase 3
Phase 3 data due 1Q 2017.
AFMD
$2.00
-0.05  (-2.44%)
AFM13
Hodgkin Lymphoma - Cancer
Phase 1b
Phase 1b update due end of 2016 or early 2017.
AMAG
$34.00
+0.15  (+0.44%)
Feraheme
Adults with iron deficiency anemia (IDA)
Phase 3
Phase 3 trial to be completed early 2017. sNDA due mid 2017.
ARDX
$14.95
-0.95  (-5.97%)
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3
Phase 3 data due 1Q 2017.
ARQL
$1.33
-0.01  (-0.75%)
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 3
Phase 3 SPA agreed upon. Dosage reduced following recommendation from DMC. Top-line data due 1Q 2017.
BCRX
$5.50
-0.15  (-2.48%)
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients
Phase 2
Phase 2 data from Part 1 portion of trial due 1Q 2017.
BLPH
$0.56
+0.05  (+10.23%)
INOpulse delivery device
Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF)
Phase 2
Phase 2 initiated May 2016. Data due 1Q 2017.
BLPH
$0.56
+0.05  (+10.23%)
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2
Phase 2 initiated 3Q 2016. Data due 1Q 2017.
BLRX
$1.00
-0.02  (-1%)
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2
Phase 2 trial initiated March 2016. Partial data due 1Q 2017 with top-line results by the end of 2017.
BMRN
$82.68
-0.83  (-0.99%)
PEG-PAL
Phenylketonuria (PKU)
BLA Filing
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 1Q 2017.
BTX
$3.32
-0.08  (-2.06%)
OpRegen
Dry age-related macular degeneration (AMD)
Phase 1/2
Phase 2 second cohort underway. Data due early 2017.
CARA
$9.87
+0.03  (+0.3%)
IV CR845
Uremic pruritus
Phase 2
Phase 2/3 completion of enrollment announced November 29, 2016 with top-line data due 1Q 2017.
CCXI
$7.91
+0.31  (+4.08%)
CCX872
Non-resectable pancreatic cancer
Phase 1b
Phase 1b early response data released September 1, 2016. Initial PFS data due 1Q 2017.
CDTX
$10.70
-0.2  (-1.83%)
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 2
Phase 2 initiated June 2016. Data due 1Q 2017.
CEMP
$7.70
+0.35  (+4.76%)
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3
Phase 3 data due 1Q 2017.
CLSN
$0.67
+0.02  (+4.45%)
GEN-1 OVATION
Ovarian cancer
Phase 1b
Phase 1b data due early 2017.
CMRX
$5.17
+0.23  (+4.66%)
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3
Phase 3 interim analysis released May 2016. Final data to be presented 1Q 2017.
CRBP
$7.80
-0.05  (-0.64%)
Resunab
Cystic Fibrosis
Phase 2
Phase 2 data due 1Q 2017.
CYCC
$4.00
-0.12  (-2.91%)
Sapacitabine (SEAMLESS)
Acute myeloid leukemia - cancer
Phase 3
Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data due late 4Q 2016 or early 2017.
DERM
$30.72
+0.84  (+2.81%)
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3
Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third trial due 1Q 2017.
FGEN
$22.35
-0.2  (-0.89%)
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 3
Phase 3 data from China trial due early 2017.
GTXI
$6.51
-0.39  (-5.65%)
Enobosarm
Breast cancer - advanced ARTNBC
Phase 2
Phase 2 prelim data from Stage 1 portion of trial due 1Q 2017.
GWPH
$115.06
-3.13  (-2.65%)
Sativex
Spasticity due to cerebral palsy
Phase 2
Phase 2 data due 1Q 2017.
HALO
$11.53
-0.1  (-0.86%)
PEGPH20
Pancreatic cancer
Phase 2
Phase 3 dosing initiated March 2016. Phase 2 PFS data due likely early 2017.
IMMVF
$0.57
+0  (+0%)
DPX-Survivac and low-dose cyclophosphamide and epacadostat
Recurrent ovarian cancer
Phase 1b
Phase 1b initial data due 1Q 2017.
IRWD
$15.24
+0.35  (+2.35%)
IW-1973
Type 2 diabetes
Phase 2
Phase 2a data due 1Q 2017.
KDMN
$4.90
-0.11  (-2.21%)
Tesevatinib
EGFR-mutant non-small cell lung cancer (NSCLC) that has metastasized to the brain
Phase 2
Phase 2 data on the first 13 patients to be presented at the IASLC 17th World Conference on Lung Cancer December 6 2016, additional top-line data due 1Q 2017.
KITE
$45.89
+0.82  (+1.82%)
KTE-C19 (ZUMA-1)
Refractory Non-Hodgkin’s Lymphoma (NHL) - cancer
BLA Filing
Phase 2 pivotal top-line data released September 26, 2016. Updated data provided at ASH 2016. Primary analysis due 1Q 2017. Rolling BLA filing initiated December 2016 with completion expected 1Q 2017.
KPTI
$9.21
+0.03  (+0.33%)
Selinexor - SADAL
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2b
Phase 2b initiated Dec 2014. Preliminary topline data due early 2017.
KTOV
$3.44
-0.06  (-1.71%)
KIT-302
Osteoarthritis and Hypertension
NDA Filing
NDA Filing to be submitted by 1Q 2017.
LJPC
$18.79
+0.27  (+1.46%)
LJPC-501
Catecholamine-resistant hypotension (CRH)
Phase 3
Phase 3 data due 1Q 2017.
MESO
$4.57
-0.01  (-0.18%)
MPC-150-IM
Chronic heart failure (CHF)
Phase 3
Phase 3 interim analysis 1Q 2017.
MRUS
$15.50
-0.1  (-0.64%)
MCLA-128
Breast cancer
Phase 1/2
Phase 1/2 interim data due 1Q 2017.
NKTR
$12.95
+0.62  (+5.03%)
NKTR-181
Lower back pain
Phase 3
Phase 3 initiated late Feb 2015. Data due 1Q 2017.
NKTR
$12.95
+0.62  (+5.03%)
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3
Phase 3 data due 1Q 2017.
NOVN
$28.44
-0.62  (-2.13%)
SB204
Acne vulgaris
Phase 3
Phase 3 top-line data due 1Q 2017.
NVLS
$2.11
-0.06  (-2.76%)
N91115
Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein
Phase 2
Phase 2 data due 1Q 2017.
OCRX
$2.25
+0.15  (+7.14%)
OCR-002 (IV)
Hepatic encephalopathy
Phase 2b
Phase 2b enrollment completion announced December 7, 2016. Data due 1Q 2017.
OGXI
$0.46
+0.01  (+2.95%)
Apatorsen and Zytiga - Pacific trial
Chemotherapy-naive patients with metastatic CRPC - cancer
Phase 2
Phase 2 data to be presented early 2017.
ONCE
$55.77
+1.8  (+3.34%)
SPK-7001 (SPK-CHM)
Choroideremia
Phase 1/2
Phase 1/2 dosing commenced 1Q 2015. Initial data due early 2017.
ONCE
$55.77
+1.8  (+3.34%)
SPK-RPE65
Inherited retinal dystrophies
BLA Filing
BLA filing due early 2017.
OPK
$10.81
-0.12  (-1.11%)
Factor VIIa-CTP
Hemophilia
Phase 2
Phase 2 safety data due early 2017.
PGNX
$8.87
+0.31  (+3.62%)
Azedra
Pheochromocytoma
Phase 2b
Pivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding. Enrolment completed by end of 2015. Top-line data due between December 2016 and March 2017
PTCT
$12.86
+0.79  (+6.55%)
Translarna
Nonsense mutation cystic fibrosis
Phase 3
Phase 3 initiated July 2014. Enrolment completed November 2015. Data due late 1Q 2017.
PTI
$11.13
+0.37  (+3.44%)
PTI-428
Cystic fibrosis
Phase 1
Phase 1 top-line data due 1Q 2017.
QURE
$6.20
+0.37  (+6.35%)
AMT-060
Sanfilippo B
Phase 1/2
Phase 1/2 30 month follow up data due 1Q 2017.
RARE
$71.96
+0.63  (+0.88%)
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2
Phase 2 initiated March 2014. Seizure data due 1Q 2017.
RGLS
$2.60
-0.05  (-1.89%)
RG-101 and GSK2878175 - randomized
Hepatitis C virus (HCV)
Phase 2
Clinical hold placed June 2016. Expects to hear back from FDA in 1Q 2017.
RGLS
$2.60
-0.05  (-1.89%)
RG-101 with multiple approved DAAs
Hepatitis C virus (HCV)
Phase 2
Clinical hold placed June 2016. Expects to hear back from FDA in 1Q 2017.
RGLS
$2.60
-0.05  (-1.89%)
RG-101 and GSK2878175 open label
HCV
Phase 2
Clinical hold placed June 2016. Expects to hear back from FDA in 1Q 2017.
RIGL
$2.63
-0.02  (-0.75%)
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
NDA Filing
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA filing due 1Q 2017.
RTTR
$2.93
+0.37  (+14.45%)
RP-G28
Lactose intolerance
Phase 2/3
Phase 2/3 top-line data are due 1Q 2017.
SNDX
$9.03
-0.4  (-4.24%)
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 1/2
Phase 1b/2 commenced dosing June 2016. Continues to enroll as of November 2016. Phase 1b safety data due 1Q 2017.
SNDX
$9.03
-0.4  (-4.24%)
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 1/2
Phase 2 enrolling as of November 2016. Go/no go decision to progress into the second stage due 1Q 2017.
SYN
$0.81
+0  (+0.64%)
SYN-004
C. difficile Infection
Phase 2b
Phase 2b initiated September 2015. Topline data due 1Q 2017.
TCON
$5.40
-0.25  (-4.42%)
TRC105 and Avastin
Glioblastoma - cancer
Phase 2
Phase 2 data due by late 2016 or early 2017.
TRVN
$5.78
+0.28  (+5.28%)
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 3
Phase 3 APOLLO-1 and APOLLO-2 commenced June 2016. Top-line data 1Q 2017.
XBIT
$13.91
+0.07  (+0.51%)
514G3
Staphylococcus Aureus Bacteremia
Phase 1/2
Phase 1/2 enrollment completed December 2016. Top-line data due 1Q 2017.
XBIT
$13.91
+0.07  (+0.51%)
Xilonix
Colorectal cancer
Phase 3
Phase 3 completion of enrollment announced December 7, 2016 with interim analysis due 1Q 2017.
XENE
$7.80
-0.1  (-1.27%)
XEN801
Acne
Phase 2
Phase 2 initiated February 2016. Data due 1Q 2017.
XENT
$10.80
+0.2  (+1.89%)
RESOLVE steroid-releasing implant
Recurrent sinus obstruction
NDA Filing
Phase 3 endpoints met - October 2016. NDA filing due 1Q 2017.
ZSAN
$0.73
-0.02  (-2.67%)
ZP-Triptan
Migraine
Phase 3
Pivotal trial data due 1Q 2017.
EYEG
$1.72
+0.11  (+6.83%)
EGP-437
Non-infectious anterior uveitis
Phase 3
Phase 3 enrolment commenced January 2016. Top-line data due 1Q 2017
MDCO
$32.82
-0.56  (-1.65%)
CARBAVANCE
Complicated urinary tract infections (cUTI)
NDA Filing
Phase 3 data met endpoints June 2016. NDA filing due early 2017
NBIX
$41.71
-1.23  (-2.86%)
NBI-98854 (Valbenazine)
Tardive dyskinesia
PDUFA
PDUFA date under priority review April 11, 2017. Advisory Committee Meeting February 16, 2016.
CAPR
$2.67
-0.16  (-5.65%)
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 1/2
Phase 1/2 enrollment completed September 2016 with data due EARLY 2Q 2017.
BMRN
$82.68
-0.83  (-0.99%)
Cerliponase alfa
Batten Disease
PDUFA
PDUFA date extended by three months to April 27 2017
ARIA
$12.68
-0.3  (-2.31%)
Brigatinib - ALTA trial
Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC)
PDUFA priority review
PDUFA date under priority review April 29, 2017.
TXMD
$6.16
-0.5  (-7.51%)
Yuvvexy
Moderate-to-severe vaginal pain
PDUFA
PDUFA date May 7, 2017.
IMDZ
$8.30
+0.2  (+2.47%)
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2
Phase 2 potential data at ASCO 2017.
IMDZ
$8.30
+0.2  (+2.47%)
CMB305
Cancer - solid tumors
Phase 2
Phase 2 potential data at ASCO 2017.
ALKS
$55.47
-0.29  (-0.5%)
Aristada
Schizophrenia
PDUFA
Approved October 5 2015. sNDA filed for 2-month option August 8 2016. PDUFA date estimate June 8, 2017.
CHRS
$28.15
+0.3  (+1.08%)
CHS-1701
Pegfilgrastim biosimilar
PDUFA
PDUFA date June 9, 2017.
MTZPY
$18.31
-0.09  (-0.47%)
Edaravone
Amyotrophic lateral sclerosis (ALS)
PDUFA
PDUFA date June 16, 2017
AERI
$36.93
-1.63  (-4.22%)
Roclatan - Mercury trials
Glaucoma
Phase 3
Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
AGLE
$5.70
-0.27  (-4.52%)
AEB1102
Arginase I deficiency
Phase 1
Phase 1 to initiated 1H 2016. Top-line data due 1H 2017
ALDR
$22.35
+0.9  (+4.2%)
ALD403 - PROMISE 1
Frequent episodic migraine
Phase 3
Phase 3 PROMISE 1 topline data due 1H 2017.
ALKS
$55.47
-0.29  (-0.5%)
ALKS 6428
Opioid dependence
Phase 3
Phase 3 initated September 2015. Data due 1H 2017.
ARGS
$4.90
+0.1  (+2.08%)
AGS-003 ADAPT Trial
Metastatic renal cell carcinoma (mRCC)
Phase 3
Phase 3 overall survival analysis due 1H 2017.
ARGS
$4.90
+0.1  (+2.08%)
AGS-003
Early stage renal cell carcinoma (RCC) - cancer
Phase 2
Phase 2 trial initial data due 1H 2017.
AXSM
$6.70
-0.1  (-1.47%)
AXS-02
Complex regional pain syndrome (CRPS)
Phase 3
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 1Q or 2Q 2017.
AZRX
$4.59
+0.16  (+3.64%)
MS1819-SD
Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)
Phase 2
Phase 2 trial initiated November 2016. Initial data due 1H 2017.
BTX
$3.32
-0.08  (-2.06%)
Renevia
Restoring normal skin contours in for patients with HIV
Phase 3
Pivotal trial data due 1H 2017.
BVXV
$3.74
-0.01  (-0.27%)
M-001
Universal flu vaccine
Phase 2b
Phase 2b enrollment commenced March 2016. Last patient visit September, 2016. Data due in “coming months”. Estimate 1H 2017.
CAPR
$2.67
-0.16  (-5.65%)
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)
Phase 2
Phase 2 enrolling. 6 month data likely due 2Q 2017.
CARA
$9.87
+0.03  (+0.3%)
IV CR845
Acute pain
Phase 3
Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrolment resuming June 2016. Interim conditional power analysis due 1H 2017.
CARA
$9.87
+0.03  (+0.3%)
CR845
Osteoarthritis (OA)
Phase 2b
Phase 2b trial initiated September, 2016. Data are due 1H 2017.
CPRX
$1.18
+0.03  (+2.61%)
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 2/3
Phase 2/3 top-line data due 1H 2017.
CYTK
$11.25
-0.05  (-0.44%)
CK-2127107
Spinal muscular atrophy (SMA)
Phase 2
Phase 2 initiated January 2016. Enrollment to be completed 4Q 2016. Data are due 1H 2017.
CYTR
$0.53
+0  (+1.26%)
Aldoxorubicin
Relapsed/refractory small cell lung cancer
Phase 2b
Phase 2b data due 1H 2017.
EGLT
$8.77
+0.47  (+5.66%)
Egalet-002
Moderate to severe chronic pain
Phase 3
Phase 3 ongoing. Data likely 1H 2017. NDA planned for mid 2017.
EPZM
$11.10
+0.3  (+2.78%)
Tazemetostat
Solid tumors - cancer
Phase 2
Phase 2 data due 1H 2017.
EPZM
$11.10
+0.3  (+2.78%)
Tazemetostat
Relapsed or refractory B-cell NHL
Phase 2
Phase 2 futility analysis completed September 6, 2016. Futher data due 1H 2017.
FOLD
$6.09
+0.04  (+0.66%)
SD-101
Epidermolysis Bullosa (EB)
Phase 3
Phase 3 top-line data due 1H 2017.
FOMX
$10.47
+0.49  (+4.91%)
FMX101
Acne
Phase 3
Phase 3 completion of enrollment announced late November 2016. Data are due 1H 2017.
GERN
$2.08
-0.01  (-0.48%)
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2/3
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal review conducted September 2016, trial to continue as planned. Internal review due 2Q 2017.
GERN
$2.08
-0.01  (-0.48%)
Imetelstat - IMbarkStudy
Myelofibrosis
Phase 2
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Next review 2Q 2016.
GLPG
$58.95
+0.71  (+1.22%)
GLPG1690 - FLORA
Idiopathic pulmonary fibrosis
Phase 2a
Phase 2a top-line data due 2Q 2017.
GTXI
$6.51
-0.39  (-5.65%)
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2
Phase 2 initiated January 2016. Data are due 1H 2017.
GWPH
$115.06
-3.13  (-2.65%)
GWP42006 (CBDV)
Epilepsy
Phase 2
Phase 2 initiated May 2015. Data due 1H 2017.
GWPH
$115.06
-3.13  (-2.65%)
Epidiolex
Dravet Syndrome
Phase 3
Second Phase 3 trial initiated mid April 2015. Data due 2017.
GWPH
$115.06
-3.13  (-2.65%)
Epidiolex
Dravet Syndrome
NDA Filing
Top line Phase 3 data released March 2016 met primary endpoint. NDA filing 1H 2017.
IONS
$45.57
-0.99  (-2.13%)
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Phase 3
Phase 3 to be completed in 1H 2017.
KURA
$5.20
-0.1  (-1.89%)
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2
Phase 2 top-line data due 1H 2017.
KURA
$5.20
-0.1  (-1.89%)
Tipifarnib
HRAS mutant solid tumors - cancer
Phase 2
Phase 2 top-line data due 1H 2017.
MDGN
$5.35
+0.09  (+1.71%)
NFC-1
22q11.2 Deletion Syndrome
Phase 1/2
Phase 1b data due 1H 2017.
MESO
$4.57
-0.01  (-0.18%)
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 3
Phase 3 trial to be completed 1H 2017.
NLNK
$11.01
-0.03  (-0.27%)
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 2
Phase 2 data due 1H 2017.
NOVN
$28.44
-0.62  (-2.13%)
SB208
Fungal infections
Phase 2
Phase 2 data due 1H 2017.
OMED
$7.64
-0.51  (-6.26%)
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 2
Phase 2 data are due 1H 2017.
OMED
$7.64
-0.51  (-6.26%)
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2 data are 1H 2017. Announced November 1, 2016 that it has discontinued further enrollment.
OMED
$7.64
-0.51  (-6.26%)
Tarextumab - PINNACLE trial
Small cell lung cancer
Phase 2
Phase 2 enrollment completed August 2016. Data due 1H 2017.
PBYI
$36.45
-3.35  (-8.42%)
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 2
Phase 2 data due 1H 2017.
PBYI
$36.45
-3.35  (-8.42%)
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 3
Phase 3 data due 1H 2017.
PRTK
$13.40
+0.05  (+0.37%)
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3
Phase 3 data due 2Q 2017.
PRTK
$13.40
+0.05  (+0.37%)
Sarecycline
Severe acne vulgaris
Phase 3
Phase 3 data due 1H 2017.
PSDV
$1.69
-0.05  (-2.87%)
Medidur
Posterior uveitis
NDA Filing
Phase 3 data released December 2015. Second Phase 3 trial data and NDA filing due 1H 2017.
RARE
$71.96
+0.63  (+0.88%)
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
NDA Filing
Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. NDA filing due 1H 2017.
RARE
$71.96
+0.63  (+0.88%)
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Phase 3
Phase 3 enrolment completed July 2016. Data due 1H 2017.
RDHL
$11.29
+0.01  (+0.09%)
RIZAPORT (RHB-103)
Migraine
NDA Filing
Planned resubmission of NDA due 1H 2017.
RETA
$21.57
-1  (-4.43%)
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2
Phase 2 initial data due 1H 2017.
RETA
$21.57
-1  (-4.43%)
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 2
Phase 2 initial data due 1H 2017.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-547
Major Depressive Disorder (MDD)
Phase 2
Phase 2 initiation 4Q 2016. Data due 1H 2017.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-217
Parkinson’s disease (PD)
Phase 2
Phase 2 initiation 4Q 2016. Data due 1H 2017.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-547
SRSE
Phase 3
Phase 3 data due 1H 2017.
SBPH
$7.65
-0.25  (-3.16%)
SB 9200
Hepatitis B (HBV)
Phase 2a
Phase 2a data due 1H 2017.
SELB
$23.15
-0.05  (-0.22%)
SEL-212
Tophaceous gout
Phase 2
Phase 2 dosing commenced late October 2016. Initial data due 1H 2017.
SGEN
$66.93
+1.84  (+2.83%)
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
sNDA Filing
Phase 3 data released August 2016. sNDA to be filed 1H 2017.
TGTX
$5.20
+0.05  (+0.97%)
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3
Phase 3 enrollment completed December 2016. Data due 1H 2017.
VKTX
$1.11
-0.04  (-3.48%)
VK2809
Hypercholesterolemia
Phase 2
Phase 2 to be completed 2Q 2017.
VKTX
$1.11
-0.04  (-3.48%)
VK5211
Acute Hip Fracture
Phase 2
Phase 2 to be completed 2Q 2017.
VNDA
$15.90
+0.5  (+3.25%)
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis
Phase 2
Phase 2 data due in 2017.
VRTX
$77.22
+1.9  (+2.52%)
VX-661
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 3
Phase 3 data due 1H 2017.
VRTX
$77.22
+1.9  (+2.52%)
VX-661
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 3
Phase 3 data due 1H 2017.
VSTM
$1.16
-0.02  (-1.69%)
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 3
Phase 3 data due 1H 2017.
XENE
$7.80
-0.1  (-1.27%)
TV-45070
Postherpetic neuralgia
Phase 2b
Phase 2b initiated late March 2015. Data due 1H 2017.
XLRN
$31.48
+0.52  (+1.68%)
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 preliminary data due 1H 2017.
ZGNX
$12.35
-0.65  (-5%)
ZX008 - (Study 1502)
Dravet syndrom
Phase 3
Phase 3 data due 2Q 2017.
ZGNX
$12.35
-0.65  (-5%)
ZX008 - Study 1501
Dravet syndrom
Phase 3
Phase 3 data due 2Q 2017.
ZYNE
$7.30
+0  (+0%)
ZYN002
Fragile X syndrome
Phase 2
Phase 2 to be initiated 2H 2016. Data are due 1H 2017.
ZYNE
$7.30
+0  (+0%)
ZYN002
Osteoarthritis
Phase 2
Phase 2 initiated September 2016. Data are due 1H 2017.
ZYNE
$7.30
+0  (+0%)
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2
Phase 2 dosing commenced August 2016. Data are due 1H 2017.
ARRY
$8.66
-0.08  (-0.8%)
Binimetinib (NEMO)
NRAS melanoma - cancer
PDUFA
PDUFA date June 30, 2017
BPMX
$0.42
+0  (+0%)
BPX-01
Acne
Phase 2b
Phase 2b to be initiated August 2016. Data due 1H 2017
PBYI
$36.45
-3.35  (-8.42%)
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer
PDUFA
PDUFA date July 21, 2017.
ALNY
$42.25
+1.44  (+3.54%)
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3
Phase 3 data due mid 2017.
ARDX
$14.95
-0.95  (-5.97%)
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3
Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due later that year.
ARRY
$8.66
-0.08  (-0.8%)
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 3
Phase 3 data released September 26, 2016 met primary endpoint. NDA filing due 2017. Data from Part 2 portion of trial due mid-2017.
ATNM
$0.99
+0  (+0%)
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 2
Phase 2 initiated September 2016. Interim analysis due mid-2017.
CYTX
$1.60
+0.04  (+2.56%)
ECCS-50
Scleroderma
Phase 3
Pivotal trial initiated August 2015. Enrolment completed June 2016. Data are due mid 2017.
FGEN
$22.35
-0.2  (-0.89%)
FG-3019
Idiopathic pulmonary fibrosis
Phase 2
Phase 2 ongoing. Two-thirds of patients enrolled as of February 2016. Enrolment to be completed 3Q 2016. Data due mid 2017.
GTXI
$6.51
-0.39  (-5.65%)
Enobosarm
Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer
Phase 2
Phase 2 initial data released December, 8 2016. Top-line data from full trial due mid 2017.
IMGN
$1.84
-0.05  (-2.65%)
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 1/2
Phase 1b/2 initial data due mid 2017.
KMDA
$5.85
+0  (+0%)
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2/3
Phase 2/3 data due mid-2017.
KPTI
$9.21
+0.03  (+0.33%)
Selinexor - SEAL
Dedifferentiated liposarcoma
Phase 2/3
Phase 2/3 trial initiated January 2016. Top-line data for the Phase 2 portion due mid-2017.
KPTI
$9.21
+0.03  (+0.33%)
Selinexor SOPRA
Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 2
Phase 2 initiated June 25 2014. Top-line data due mid 2017.
ONCE
$55.77
+1.8  (+3.34%)
SPK-8011
Hemophilia A
Phase 1/2
Phase 1/2 trial to be initiated 4Q 2016 with initial data due mid 2017.
PRQR
$4.40
-0.05  (-1.13%)
QR-010
Cystic Fibrosis
Phase 1b
Phase 1b top-line data due mid-2017. Open label data presented at (NACFC) October 27, 2016.
RDHL
$11.29
+0.01  (+0.09%)
BEKINDA -GUARD
Gastroenteritis
Phase 3
Phase 3 top-line data due mid-2017.
RDHL
$11.29
+0.01  (+0.09%)
BEKINDA
IBS-D
Phase 2
Phase 2 top-line data due mid 2017.
TBPH
$30.36
+1.23  (+4.22%)
Velusetrag (TD-5108)
Gastroparesis
Phase 2b
Phase 2b initiated mid March 2015. Data due mid-2017.
TCON
$5.40
-0.25  (-4.42%)
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due mid 2017.
VBLT
$4.75
-0.2  (-4.04%)
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 3
Phase 3 initiated mid 2015. Interim analysis due mid 2017. Full data late in 2017 or early 2018
VYGR
$15.02
+1.29  (+9.4%)
VY-AADC01
Advanced Parkinson’s disease
Phase 1b
Phase 1b trial onoging. Promising interim data released December 7, 2016. Cohort 3 data due mid-2017. Placebo trial to commence 4Q 2017.
WINT
$1.33
+0  (+0%)
Aerosurf
Respiratory Distress Syndrome - premature infants 26 to 32 weeks
Phase 2b
Announced October 25, 2016 data delay. Phase 2b top-line data now due mid 2017.
ALNY
$42.25
+1.44  (+3.54%)
ALN-HBV
Chronic hepatitis B virus (HBV)
Phase 1/2
Phase 1/2 trial initiated July 2016. Data are due mid 2017
KMDA
$5.85
+0  (+0%)
KamRAB
Prophylaxis of rabies disease
PDUFA
PDUFA date August 29, 2017.
REPH
$6.61
-0.38  (-5.44%)
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
NDA Filing
Phase 3 data from second trial released November 28, 2016. Primary endpoint met. Safety study to be completed by 1Q or early 2Q 2017, with an NDA filing due summer 2017.
ABIO
$2.40
+0.05  (+2.13%)
Gencaro - GENETIC-AF trial
Chronic Heart Failure
Phase 2b
Phase 2b interim analysis due 3Q 2017.
AMRN
$3.22
-0.04  (-1.23%)
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia
Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due 3Q 2017. Final data due 2018.
CRBP
$7.80
-0.05  (-0.64%)
Resunab
Dermatomyositis
Phase 2
Phase 2 data due 3Q 2017.
PRTK
$13.40
+0.05  (+0.37%)
Omadacycline
Community-acquired bacterial pneumonia (CABP)
Phase 3
Phase 3 initiated November 2015. Data are due 3Q 2017.
SMMT
$9.98
-0.21  (-2.06%)
Ezutromid
Duchenne muscular dystrophy
Phase 2
Phase 2 24-week data due 2Q or 3Q 2017.
VSAR
$13.30
+0.4  (+3.1%)
VRS-317 VELOCITY
Growth hormone deficiency, or GHD - pediatric
Phase 3
Phase 3 top-line data due 3Q 2017.
SYRS
$16.54
-0.11  (-0.66%)
SY-1425
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer
Phase 2
Phase 2 initiated September 2016. Preliminary data due fall of 2017.
AIMT
$23.08
-0.01  (-0.04%)
AR101
Peanut Allergy
Phase 3
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 4Q 2017.
APRI
$1.14
-0.06  (-5%)
Vitaros
Erectile dysfunction
NDA Filing
NDA resubmission planned for 2H 2017.
AQXP
$14.73
+0.07  (+0.48%)
AQX-1125 LEADERSHIP
Bladder pain syndrome/interstitial cystitis (BPS/IC).
Phase 3
Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Top-line data due 4Q 2017.
ARIA
$12.68
-0.3  (-2.31%)
AP32788
Non-small cell lung cancer (NSCLC)
Phase 1/2
Phase 1/2 initial data due in 2017.
ARNA
$1.42
+0.04  (+3.28%)
APD334
Ulcerative colitis
Phase 2
Phase 2 data due 2017.
AXON
$14.25
-0.08  (-0.57%)
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2
Phase 2 data due 2017.
AXON
$14.25
-0.08  (-0.57%)
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2b
Phase 2b data due 2017.
AXON
$14.25
-0.08  (-0.57%)
Intepirdine - MINDSET
Alzheimer’s disease
Phase 3
Phase 3 initiated October 2015. Data are due 2017.
BLPH
$0.56
+0.05  (+10.23%)
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 3
Phase 3 commenced enrolment June 2016. Interim data due 4Q 2017 with top-line data due mid-2018.
BLRX
$1.00
-0.02  (-1%)
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2
Phase 2 initiated September 2016. Partial data due 2H 2017.
CALA
$3.20
-0.05  (-1.54%)
CB-839 + nivolumab
Phase 1/2
Phase 1/2 enrollment commenced August 2016. Initial data due in 2017.
CDTX
$10.70
-0.2  (-1.83%)
CD101 IV - STRIVE
Candidemia
Phase 2
Phase 2 initiated June 2016. Data due 4Q 2017.
CERU
$0.78
+0.03  (+4%)
CRLX301
Solid tumours - cancer
Phase 2a
Phase 2a portion of Phase 1/2a trial commenced dosing June 2016. Initial data due in 2017.
CERU
$0.78
+0.03  (+4%)
CRLX101, in combination with LYNPARZA
Solid tumors - cancer
Phase 1/2
Phase 1/2 trial commenced dosing May 2016. Top-line data due 2017.
CERU
$0.78
+0.03  (+4%)
CRLX101 and paclitaxel
Platinum-resistant ovarian cancer
Phase 2
Further data due in 2017.
CLCD
$36.00
-3.7  (-9.32%)
Lasmiditan - SPARTAN
Migraine
Phase 3
Phase 3 top-line data 2H 2017.
CLRB
$1.37
-0.01  (-0.72%)
CLR 131
Various lymphoma
Phase 2
Phase 2 trial to be initiated 1Q 2017. Initial data due 2H 2017.
CLSD
$11.53
-2.9  (-20.11%)
CLS-1001
Macular edema associated with non-infectious uveitis
Phase 3
Phase 3 data due 2H 2017.
CLVS
$36.46
-0.88  (-2.36%)
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
Phase 3
Pivotal trial initiated late 2013. Enrollment completed 2Q 2016. Data due 2H 2017.
CNCE
$8.92
+0.01  (+0.11%)
CTP-656
Cystic fibrosis
Phase 2
Phase 2 planned for 4Q 2016. Data due by end of 2017.
CPRX
$1.18
+0.03  (+2.61%)
Firdapse
Congenital Myasthenic Syndromes (CMS)
Phase 3
Phase 3 data due 2H 2017.
CPRX
$1.18
+0.03  (+2.61%)
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)
Phase 3
Refusal to file letter reported on Feb 17 2016 for Dec 2015 NDA Filing. Additional Phase 3 trial planned for 4Q 2016. Data due 2H 2017.
CRIS
$2.91
-0.17  (-5.52%)
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)
Phase 2
Phase 2 data due 2017
CUR
$0.24
-0.01  (-2.64%)
NSI-189
Major depressive disorder
Phase 2
Phase 2 initiated March 2016. Data are due 2H 2017.
CYTK
$11.25
-0.05  (-0.44%)
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 3
Phase 3 data are due 4Q 2017.
CYTR
$0.53
+0  (+1.26%)
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
NDA Filing
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Overall survival data and NDA filing due 2017.
DBVT
$36.71
+0.53  (+1.46%)
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 1/2
Phase 1/2 data due 2H 2017.
DBVT
$36.71
+0.53  (+1.46%)
Viaskin Peanut
Peanut allergy
Phase 3
Phase 3 data due 2H 2017.
DERM
$30.72
+0.84  (+2.81%)
DRM04
Primary axillary hyperhidrosis
NDA Filing
Phase 3 data released June 2016. NDA Filing 2H 2017.
EARS
$1.29
-0.02  (-1.53%)
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3
Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway.
EIGR
$11.90
-0.75  (-5.93%)
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2
Phase 2 initiated July 2016. Data due 2017.
EIGR
$11.90
-0.75  (-5.93%)
Ubenimex - ULTRA
Secondary lymphedema
Phase 2
Phase 2 dosing commenced July 2016. Data due 2017.
EXEL
$16.84
-0.08  (-0.41%)
XL184 cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Phase 3
Phase 3 initiated Sept 2013. Data due 2017.
FPRX
$53.79
+0.32  (+0.6%)
FP-1039
Mesothelioma cancer
Phase 1b
Phase 1b NSCLC halted, mesothelioma to continue. Noted in filing released December 6, 2016 that data are due 2H 2017.
GALT
$0.94
+0.06  (+7.93%)
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 2
Phase 2 top-line data due December 2017.
GBT
$16.25
+0  (+0%)
GBT440
Sickle cell disease in adolescents
Phase 1/2
Phase 2a initiated June 2016. Data due 2017
GNVC
$3.14
-0.08  (-2.48%)
CGF166
Hearing loss
Phase 1/2
Trial halted January 2016 due to safety review. Clinical hold released July 2016 with trial completion due in 2017.
ICPT
$106.04
+3.3  (+3.21%)
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)
Phase 2
Phase 2 data due 2017.
ITEK
$6.80
-0.15  (-2.16%)
Trabodenoson and latanoprost
Glaucoma
Phase 2
Phase 2 initiated July 2016. Data due 2H 2017.
KURA
$5.20
-0.1  (-1.89%)
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer
Phase 2
Phase 2 dosing commenced June 2016. Top-line data due 2H 2017.
LBIO
$7.00
+0.4  (+6.06%)
LN-144
Refractory metastatic melanoma
Phase 2
Phase 2 continues to enrol as of October 2016. Initial data to be presented in 2017.
MACK
$5.48
+0.07  (+1.29%)
MM-302 HERMIONE
Cancer - HER2-positive locally advanced or metastatic breast cancer
Phase 2
Phase 2 initiated August 2014. Data due 2017 - FULL COMPANY PIPELINE UPDATE DUE BY END OF 2016.
MACK
$5.48
+0.07  (+1.29%)
ONIVYDE
Cancer - front line pancreatic
Phase 2
Phase 2 initiated October 2015. Data due 2017 - FULL COMPANY PIPELINE UPDATE DUE BY END OF 2016.
MATN
$0.31
-0.04  (-11.41%)
CA4P Fosbretabulin - FOCUS
Cancer - Platinum-Resistant Ovarian Cancer
Phase 2/3
Phase 2/3 trial commenced June 2016. Data due 2H 2017.
MBRX
$2.40
-0.1  (-4%)
Annamycin
Acute myeloid leukemia (AML) - cancer
Phase 2
Phase 2 data due 2H 2017.
MCRB
$9.69
-0.09  (-0.92%)
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 1b
Phase 1b initiated July 2016. Data due 2017
MCRB
$9.69
-0.09  (-0.92%)
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 1b
Phase 1b initiated December 2015. Enrolment ongoing as of May 2016. Data due 2017.
MNOV
$7.45
-0.13  (-1.72%)
MN-166
Progressive multiple sclerosis (progressive MS)
Phase 2b
Interim data presented December 9, 2016. 6-month data due in 2017.
MRUS
$15.50
-0.1  (-0.64%)
MCLA-128
Solid tumors
Phase 1/2
Phase 1/2 top-line data due 2H 2017.
MRUS
$15.50
-0.1  (-0.64%)
MCLA-117
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2 interim data due 2H 2017.
MSTX
$0.12
+0.03  (+42.68%)
AIR001
Heart failure with preserved ejection fraction (HFpEF)
Phase 2
Phase 2 data due 4Q 2017.
MYOK
$14.50
-0.8  (-5.23%)
MYK-461 - PIONEER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2
Phase 2 dosing initiated November 2016. Top-line data due 2H 2017.
NBIX
$41.71
-1.23  (-2.86%)
Elagolix
Uterine Fibroids
Phase 3
Phase 3 initiated by partner Abbvie in January 2016. Data due in 2017.
NBIX
$41.71
-1.23  (-2.86%)
Elagolix
Endometriosis
NDA Filing
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA filing due 2017.
NBRV
$4.61
+0.3  (+6.96%)
Lefamulin
Moderate to severe Community Acquired Bacterial Pneumonia (CABP)
Phase 3
Phase 3 top line data from two trials due 2H 2017.
NEOT
$1.04
-0.11  (-9.57%)
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2
Phase 3 endpoints not met December 2015. Phase 2 trial to be initiated December 2016 with data due in 2Q 2017.
NLNK
$11.01
-0.03  (-0.27%)
Indoximod + temozolomide
Glioblastoma multiforme cancer
Phase 2
Phase 2 data due 2H 2017.
OTIC
$17.40
+1.2  (+7.41%)
OTO-104 AVERTS-1 and AVERTS-2
Ménière’s disease
Phase 3
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
PLX
$0.30
-0.01  (-0.97%)
OPRX-106
Ulcerative Colitis
Phase 2
Phase 2 trial initiation announced November 30, 2016. Data due 2H 2017.
PSTI
$1.51
-0.04  (-2.58%)
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 2
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PTN
$0.58
+0  (+0.64%)
Bremelanotide
Female sexual dysfunction (FSD)
NDA Filing
Phase 3 data released November 1, 2016. NDA filing due 2H 2017.
RARE
$71.96
+0.63  (+0.88%)
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3
Phase 3 data due 2H 2017.
RETA
$21.57
-1  (-4.43%)
Bardoxolone methyl
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 2
Phase 2 data due 2H 2017.
RETA
$21.57
-1  (-4.43%)
Omaveloxolone - REVEAL
Metastatic melanoma
Phase 1/2
Phase 1/2 data due 2H 2017
RIGL
$2.63
-0.02  (-0.75%)
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 2
Phase 2 data from first of two stages due in 2017.
RTRX
$20.75
+0.24  (+1.17%)
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
NDA Filing
NDA filing due 2017
RVNC
$17.20
+0.4  (+2.38%)
RT002
Plantar fasciitis
Phase 2
Phase 2 data due 2017.
RVNC
$17.20
+0.4  (+2.38%)
RT002 - SAKURA
Moderate to severe glabellar (frown) lines
Phase 3
Phase 3 initiation of dosing announced December 7, 2016. Data due 4Q 2017.
RXII
$1.70
-0.05  (-2.86%)
RXI-109-1501
Retinal scarring
Phase 1/2
Phase 2 enrolling as of November 2016. Data readout due 2H 2017.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-217
Postpartum depression (PPD)
Phase 2
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-547
Postpartum Depression
Phase 2
Phase 2 trial met primary endpoint July 2016. 202B and 202C trial data due 2H 2017 with NDA filing due in 2018.
SAGE
$51.58
-0.46  (-0.88%)
SAGE-547
Essential tremor
Phase 2
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SCYX
$3.53
+0.01  (+0.28%)
SCY-078
Invasive candidiasis
Phase 2
Phase 2 trial to be initiated 1Q 2017 with data due 4Q 2017.
SGEN
$66.93
+1.84  (+2.83%)
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 3
Phase 3 data due in 2017.
SNDX
$9.03
-0.4  (-4.24%)
E2112
HR+, HER2- breast cancer
Phase 3
Phase 3 PFS data due 2H 2017.
SNGX
$3.10
+0.04  (+1.31%)
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3
Phase 3 data due 2H 2017.
SPHS
$2.75
+0.01  (+0.36%)
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 2
Phase 2b initial data due end of 2017.
TBPH
$30.36
+1.23  (+4.22%)
Revefenacin
COPD
Phase 3
Phase 3 trials met primary endpoint. 12 month safety trial data and NDA filing both due in 2017.
TCON
$5.40
-0.25  (-4.42%)
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2
Phase 2 dosing initiated May 2016 with data due 2017.
TCON
$5.40
-0.25  (-4.42%)
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2
Phase 2 planned for 2016. Data due 2H 2017.
TCON
$5.40
-0.25  (-4.42%)
TRC102 and Temodar
Glioblastoma - cancer
Phase 2
Phase 2 trial initiated January 2016. Data due 2017.
TCON
$5.40
-0.25  (-4.42%)
TRC102
Mesothelioma cancer
Phase 2
Phase 2 initiated October 2015. Data are due in 2017.
TNXP
$0.46
+0.05  (+11.22%)
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 3
First of two Phase 3 trials to be initiated in military-related PTSD 1Q 2017. First interim analysis due 2H 2017.
TSRO
$131.54
-3.31  (-2.46%)
Niraparib - BRAVO
Cancer - breast
Phase 3
Phase 3 data due 2H 2017.
TSRO
$131.54
-3.31  (-2.46%)
Niraparib - (QUADRA trial)
Cancer - ovarian
Phase 2
Phase 2 data due 2H 2017.
TTPH
$4.63
+0.14  (+3.12%)
Eravacycline (TP-434)
cIAI (complicated intra-abdominal infections)
Phase 3
Announced Dec 17, 2014 that their Phase 3 trial met endpoints. Additional Phase 3 trial required, initiated October 2016 with data 4Q 2017.
VNDA
$15.90
+0.5  (+3.25%)
Tradipitant
Gastroparesis
Phase 2
Phase 2 enrolment to commence 4Q 2016 with data due 2H 2017
VNDA
$15.90
+0.5  (+3.25%)
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 2
Phase 2 data due in 2017.
VRTX
$77.22
+1.9  (+2.52%)
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2
Phase 2 trial to be initiated with data due 2H 2017.
VRTX
$77.22
+1.9  (+2.52%)
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2
Phase 2 trial to be initiated with data due 2H 2017.
XNCR
$27.03
+0.15  (+0.56%)
XmAb5871
IgG4-Related Disease (IgG4-RD)
Phase 2
Phase 2 trial initiated March 2016. Preliminary data released November 13, 2016. Additional data due in 2017.
AVEO
$0.63
+0.01  (+2.56%)
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3
CRL June 10 2013. Phase 3 dosing commenced May 2016. Data due 1Q 2018.
CLBS
$3.73
-0.06  (-1.36%)
CLBS03
Type 1 diabetes
Phase 2
Phase 2 enrollment of first cohort completed September 2016. Second cohort commenced enrollment October 2016. Interim analysis due late 2017 or early 2018.
EARS
$1.29
-0.02  (-1.53%)
AM-101 - TACTT3
Acute inner ear tinnitus
Phase 3
Phase 3 TACTT3 enrollment to resume in early 2017 with top-line results expected in early 2018.
GLMD
$3.29
-0.22  (-6.27%)
Aramchol - ARREST
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b
Initiated Phase 2b March 2015. Interim safety analysis due 1Q 2017. Final data due 1Q 2018.
IDRA
$1.69
+0.01  (+0.6%)
IMO-8400
Dermatomyositis
Phase 2
Phase 2 initiated November 2015. Enrollment to be completed by the end of 2017 with data due early 2018.
KPTI
$9.21
+0.03  (+0.33%)
Selinexor - STORM
Quadruple Refractory Multiple Myeloma
Phase 2
Phase 2 positive top-line data released September 6, 2016. Updated data at ASH - Oral Presentation, Sunday, December 4, 2016 at 5:30 PM PT. Top-line data from expansion cohort due early 2018.
PRTA
$54.84
+1.65  (+3.1%)
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 2b
Phase 2b data due early 2018.
VICL
$2.46
+0.12  (+5.13%)
ASP0113 Vaccine
Hematopoietic cell transplant recipients
Phase 3
Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q 2018.
VTVT
$5.35
+0.21  (+4.09%)
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 3
Phase 3 initiated 2Q 2015. Part A enrollment completed September 2016. Data from Part A due early 2018. Part B due late 2018.
ALDR
$22.35
+0.9  (+4.2%)
ALD403 - PROMISE 2
Frequent episodic migraine
Phase 3
Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
ALKS
$55.47
-0.29  (-0.5%)
ALKS 8700
Multiple sclerosis (MS)
Phase 3
Phase 3 trial to be initiated 2017 with data and NDA filing due 2018. BPC estimate of data mid-2018.
ATNM
$0.99
+0  (+0%)
Iomab-B
Hematopoietic Stem Cells Transplantation
Phase 3
Phase 3 initiated June 2016. Data due 1H 2018.
CFRX
$2.20
-0.1  (-4.35%)
CF-301
Serious infections caused byStaph aureus including MRSA
Phase 2
Phase 2 to be initiated 4Q 2016 with data due 2Q 2018.
CNAT
$1.94
+0.03  (+1.57%)
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b
Phase 2b initiated May 2014. Topline data due 1H 2018.
EARS
$1.29
-0.02  (-1.53%)
AM-111 ASSENT
Acute inner ear hearing loss
Phase 3
Phase 3 ASSENT data due 1H 2018.
EBIO
$2.22
-0.08  (-3.06%)
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3
Phase 3 top-line data due 1H 2018.
MDWD
$4.90
-0.25  (-4.85%)
NexoBrid
Severe burns
Phase 3
Phase 3 initiated mid April 2015. Data due 1H 2018.
OCUL
$9.28
-0.09  (-0.96%)
OTX-TP
Glaucoma and ocular hypertension
Phase 3
Phase 3 initiated October 2016. Data due 1H 2018.
RETA
$21.57
-1  (-4.43%)
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 3
Phase 3 commenced enrolment October 2016 with data due 1H 2018.
RGLS
$2.60
-0.05  (-1.89%)
RG-012
Alport Syndrome
Phase 2
Phase 2 interim data due 1H 2018.
SGEN
$66.93
+1.84  (+2.83%)
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Phase 3
Phase 3 enrollment completed November 2016. Data are due 2017 or 2018.
VTL
$5.05
+0.05  (+1%)
VTI-308
Alcohol-induced liver decompensation, or AILD
Phase 3
Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018
ESPR
$12.22
+0.28  (+2.43%)
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3
Phase 3 efficacy studies to be initiated 4Q 2016. Data due mid 2018.
ESPR
$12.22
+0.28  (+2.43%)
Bempedoic acid (ETC-1002-040) - CLEAR Harmony
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 3
Phase 3 long-term safety and tolerability trial initiated January 2016. Top-line results due mid-2018.
HSGX
$1.86
-0.05  (-2.62%)
NeoCart
Cartilage defects in the knee
Phase 3
Phase 3 top-line data due mid 2018.
PLX
$0.30
-0.01  (-0.97%)
PRX-102
Fabry disease
Phase 3
Phase 3 dosing commenced October 2016. 1-year data due mid-2018.
CNCE
$8.92
+0.01  (+0.11%)
AVP-786
Agitation in patients with Alzheimer’s disease
Phase 3
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
BLRX
$1.00
-0.02  (-1%)
BL-8040
Consolidation treatment for AML cancer patients
Phase 2b
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
CNAT
$1.94
+0.03  (+1.57%)
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2
Phase 2b initiated November 2016. Data due 2018.
CNAT
$1.94
+0.03  (+1.57%)
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2
Phase 2 trial initiated January 2016. Data are due 2018.
IMGN
$1.84
-0.05  (-2.65%)
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3
Phase 3 data due in 2018.
INCY
$100.61
-2.27  (-2.21%)
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 3
Phase 3 initiated June 2016. Initial data due 2018
KITE
$45.89
+0.82  (+1.82%)
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2
Phase 2 pivotal initiated November 2015. Data due 2018.
MACK
$5.48
+0.07  (+1.29%)
MM-141
Cancer - front line pancreatic cancer
Phase 2
Phase 2 data due 2018 - FULL COMPANY PIPELINE UPDATE DUE BY END OF 2016.
MACK
$5.48
+0.07  (+1.29%)
MM-121
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Phase 2
Phase 2 initiated mid Feb 2015. Data due 2018 - FULL COMPANY PIPELINE UPDATE DUE BY END OF 2016.
MGNX
$27.22
+0.75  (+2.83%)
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 3
Phase 3 enrolling. Completion of trial expected in 2018
ONTX
$2.65
+0.1  (+3.92%)
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3
Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Completion of trial expected in 2018.
SNGX
$3.10
+0.04  (+1.31%)
SGX203
Pediatric Crohn’s Disease
Phase 3
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding.
TBPH
$30.36
+1.23  (+4.22%)
Telavancin
Bacteremia
Phase 3
Phase 3 data due 2018
XNCR
$27.03
+0.15  (+0.56%)
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2
Phase 2 trial initiated March 2016. Initial data due 2018.
GBT
$16.25
+0  (+0%)
GBT440 - HOPE
Sickle cell disease in adults
Phase 3
Phase 1/2 updated data at ASH 2016. Phase 3 trial to be initiated in December 2016 with top-line data due 1H 2019.
AKBA
$8.57
+0.05  (+0.59%)
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3
Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
AKBA
$8.57
+0.05  (+0.59%)
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
Phase 3
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
FOLD
$6.09
+0.04  (+0.66%)
Migalastat HCl monotherapy (012)
Fabry Disease
Phase 3
Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
IMGN
$1.84
-0.05  (-2.65%)
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3
Phase 3 data due in 2019.
KMDA
$5.85
+0  (+0%)
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)
Phase 2/3
Announced November 2, 2016 that Phase 2/3 enrollment to start imminently with data due 2020.